Live Attenuated Zika Virus Vaccines


Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.

Key Benefits

  • Reduces neurotropism from Zika virus.
  • High safety and immunogenicity of chimeric vaccines.

Market Summary

Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue (DEN) and tick-borne encephalitis (TBE) viruses. Mostly, it is spread by the bite of an infected mosquito, but it can also spread through sexual contact. In addition, Zika can be passed from a pregnant woman to her fetus and infection during pregnancy can cause birth defects including microcephaly. One in five people show symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pinkeye).

Technical Summary

Emory researchers are developing live attenuated Zika virus (ZIKV) vaccines. This yellow fever virus (YFV)-based vaccine will be constructed by introducing two types of genetic modifications into the 17D YFV genome. First, genes are replaced to generate the YF-ZK chimera virus. Second, a series of gene mutations known to reduce the neurotropism of Japanese encephalitis virus will be introduced to the YF-ZK chimera virus in order to abolish potential neurotropism. This development can provide safe and effective YFV-based live attenuated ZIKV vaccines.

Developmental Stage

Preclinical development is in progress.

Patent Information

App Type Country Serial No. Patent No. File Date Issued Date Patent Status
Nationalized PCT - United States United States 16/770,164 11,491,217 6/5/2020 11/8/2022 Issued
Tech ID: 16129
Published: 11/2/2020